Study guide
2.1 CSA Schedules I–V & MN Alignment
Minnesota MPJE Pharmacy Jurisprudence
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the Minnesota MPJE 1.2 NABP Competency Areas & Weights 1.3 How to Use This Guide & Study Strategy
2 Federal Controlled Substances Foundations
2.1 CSA Schedules I–V & MN Alignment 2.2 DEA Registration, Forms 222/106/41 & Security 2.3 Federal CS Prescription Rules (CII–CV) 2.4 Inventories, Recordkeeping & Theft/Loss
3 Federal Drug Regulation, Privacy & Supply Chain
3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration 3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor 3.3 HIPAA Privacy for Pharmacy 3.4 DSCSA & Drug Supply Chain Integrity
4 MN Board, Licensure & Eligibility
4.1 Minnesota Board of Pharmacy Authority & Sources of Law 4.2 Pharmacist Licensure by Exam & Score Transfer 4.3 License Transfer (Reciprocity) & Background Checks 4.4 Interns, Preceptors & 1,600-Hour Experience
5 Renewal, CE, PIC & Discipline
5.1 License Renewal & 30-Hour Biennial CE 5.2 Pharmacist-in-Charge Duties 5.3 Discipline & Unprofessional Conduct 5.4 HPSP, Impaired Practitioners & Mandatory Reporting
6 Technicians, Interns & Supervision
6.1 Technician Registration, Training & CE 6.2 Supervision Ratios (Statute 151.102 & Rule 6800.3850) 6.3 Intern Scope, Delegation & Certification of Accuracy
7 Prescription Authority & Validity
7.1 Who May Prescribe in Minnesota 7.2 Prescription Content & Validity Requirements 7.3 Controlled Substance Prescribing (Chapter 152 + Federal) 7.4 Refills, Partial Fills & Quantity Limits
8 Advanced MN Pharmacist Practice
8.1 Collaborative Practice Agreements & Medication Therapy Management 8.2 Pharmacist Prescriptive Authority (Minn. Stat. 151.37) 8.3 Immunizations & Vaccine Administration 8.4 Drug Administration & Therapy Management
9 Counseling, DUR & Patient Safety
9.1 Patient Counseling Requirements (Rule 6800.0910) 9.2 Prospective Drug Utilization Review 9.3 Returning & Reusing Drugs (Rule 6800.2700)
10 MN PMP & Opioid Public-Health Laws
10.1 Minnesota PMP Overview, Reporting & Pharmacist Use 10.2 Naloxone Access, Steve’s Law & Opioid Antagonists 10.3 Legitimate Medical Purpose & Red Flags
11 Dispensing: Transfers, Labels & Substitution
11.1 Prescription Transfers Between Pharmacies 11.2 Labeling & Packaging of Dispensed Drugs 11.3 Generic Substitution & Product Selection 11.4 Emergency Dispensing, OTC/BTC & Pseudoephedrine
12 Pharmacy Operations & Facilities
12.1 Pharmacy Permits, Classifications & Inspections 12.2 Security, Delivery & Work Conditions 12.3 Operational Recordkeeping & Inventories 12.4 Central Fill, Centralized Processing & Automation
13 Compounding & Hazardous Drugs
13.1 Sterile, Nonsterile & Hazardous Compounding 13.2 Minnesota Compounding Rules & Beyond-Use Dates
14 Test-Day Strategy & Final Review
14.1 When Minnesota Law Is Stricter Than Federal Law 14.2 Test-Day Strategy & Common Traps
2.1 CSA Schedules I–V & MN Alignment
Key Takeaways Explain This Topic AI
The federal Controlled Substances Act (CSA) places drugs into Schedules I–V based on accepted medical use, abuse potential, and dependence liability
Schedule I drugs have no accepted medical use under federal law and cannot be prescribed; Schedules II–V may be prescribed under increasingly less restrictive rules
Pharmacists and prescribers share corresponding responsibility for the proper prescribing and dispensing of every controlled-substance prescription
Minnesota chapter 152 aligns state schedules with the federal framework while the MN PMP requires reporting of Schedules II–V plus butalbital and gabapentin
- On the MN MPJE, when Minnesota law is stricter than federal law, answer under the prevailing Minnesota rule
- Last updated: November 2026
2.1 CSA Schedules I–V & MN Alignment
Quick Answer: The federal Controlled Substances Act (CSA) sorts drugs into five schedules by accepted medical use, abuse potential, and dependence liability. Schedule I agents have no accepted medical use and cannot be prescribed. Schedules II–V may be prescribed under rules that loosen as the schedule number rises. Pharmacists share corresponding responsibility with the prescriber. Minnesota Stat. ch. 152 tracks this framework, and the Minnesota Prescription Monitoring Program (PMP) captures Schedules II–V plus butalbital and gabapentin. On the MPJE, apply the stricter Minnesota rule when state and federal standards differ.
Controlled-substance law is a major MPJE weight because almost every dispensing, ordering, inventory, and diversion scenario starts with one question: what schedule is the drug, and which federal floor applies? This section builds that foundation and ties it to Minnesota so later chapters on prescribing, PMP, and operations make sense.
Why Scheduling Exists
Congress enacted the CSA (Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970) to create a closed system of distribution. Every controlled substance should move only among DEA-registered entities and, at the end of the chain, to a patient with a valid prescription (or under another lawful exception). Scheduling is the risk classification that drives:
- Whether a drug can be prescribed at all
- Whether DEA Form 222 / CSOS is required to order it
- Whether refills are allowed
- How tightly inventory counts and security must be applied
- How prescriptions and records must be filed
If you mis-schedule a drug on an exam vignette, every downstream answer about refills, partial fills, and ordering forms is likely wrong. Treat schedule as the first decision tree branch.
- The Five Federal Schedules
- Schedule I (CI)
Schedule I substances have:
- High potential for abuse
- No currently accepted medical use in treatment in the United States
- Lack of accepted safety for use under medical supervision
Classic examples include heroin, LSD, MDMA (ecstasy), and peyote. For marijuana/cannabis , federally marijuana in an FDA-approved drug product and marijuana subject to a state medical marijuana license have been Schedule III since April 28, 2026 (91 FR 22714); all other marijuana remains Schedule I, including adult-use cannabis that a state has legalized. For the MPJE, remember: CI drugs are not prescribed or dispensed pursuant to a federal prescription. Research and certain authorized industrial uses exist under tight DEA control, but community-pharmacy practice does not lawfully stock CI for patient dispensing.
Schedule II (CII)
Schedule II substances have:
- High potential for abuse
- Currently accepted medical use (sometimes with severe restrictions)
- Abuse that may lead to severe psychological or physical dependence
High-yield CII examples: morphine, oxycodone, hydrocodone combination products, hydromorphone, fentanyl, methadone, amphetamine, methylphenidate, cocaine (as a topical anesthetic), and certain combination products that were rescheduled into CII. CII drugs drive the strictest ordering (Form 222/CSOS), no refills , special partial-fill rules, and often the most careful security practices.
Schedule III (CIII)
Schedule III substances have abuse potential less than CI/CII, accepted medical use, and abuse that may lead to moderate or low physical dependence or high psychological dependence. Common examples: products containing limited codeine (for example, acetaminophen with codeine tablets at federal quantity limits), buprenorphine , ketamine, anabolic steroids, and certain barbiturate combinations. CIII prescriptions may be refilled under the federal 5-refill / 6-month ceiling (covered in depth in section 2.3).
Schedule IV (CIV)
Schedule IV substances have lower abuse potential relative to CIII, accepted medical use, and limited dependence liability relative to CIII. High-frequency exam drugs: benzodiazepines (alprazolam, diazepam, clonazepam, lorazepam), zolpidem and other Z-drugs, tramadol, carisoprodol, and phenobarbital. CIV follows the same federal refill framework as CIII (5 refills / 6 months).
Schedule V (CV)
Schedule V substances have the lowest abuse potential among controlled drugs, accepted medical use, and limited dependence relative to CIV. Examples include certain codeine-containing cough preparations within federal concentration limits, pregabalin, lacosamide, and other limited-quantity narcotic preparations. Federally, CV refill rules are more flexible than CIII/CIV (no automatic 5/6 hard cap), but Minnesota reporting and practice rules still treat CV as controlled —never treat “Schedule V” as “not really controlled.”
How to Reason About an Unfamiliar Drug
Exam writers love obscure brand names. You rarely need the full FDA label. Use this pattern:
Is there accepted medical use ? If not → think Schedule I (or not a drug for prescribing).
Is it a potent opioid agonist, stimulant, or high-risk pain/ADHD agent ? → often CII.
Is it a benzodiazepine, Z-drug, tramadol, or carisoprodol ? → often CIV.
Is it buprenorphine or a limited-codeine combo ? → often CIII.
Is it a low-dose narcotic cough prep or certain anticonvulsants like pregabalin ? → often CV.
When the stem gives the schedule, trust the stem —then apply the matching federal rule set.
Corresponding Responsibility
Under federal regulation (21 CFR 1306.04), a prescription for a controlled substance must be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice . The responsibility for proper prescribing and dispensing is on the prescribing practitioner , but a corresponding responsibility rests with the pharmacist who fills the prescription.
In plain language:
The prescriber must not write CS prescriptions outside legitimate practice.
The pharmacist must not knowingly dispense an invalid or illegitimate CS prescription.
“The doctor wrote it” is not a complete defense if red flags made the order clearly improper and the pharmacist ignored them.
Corresponding responsibility is the conceptual bridge to Minnesota red-flag and PMP chapters later in this guide. On federal-foundation items, expect scenarios such as: early refill requests with no clinical explanation, cash-paying patients traveling long distances for high-dose opioids, identical “pain” scripts from a single clinic for many unrelated patients, or prescriptions that look altered. Your job is not to diagnose the patient—it is to decide whether the order can lawfully be dispensed as a valid CS prescription.
Practical pharmacist steps when legitimacy is in doubt:
- Verify the prescriber’s identity, DEA registration, and authority for the schedule involved
- Contact the prescriber for clinical clarification and document the conversation
Consider a PMP query when clinically indicated or when red flags make it necessary; separately remember account-registration and dispenser-reporting duties
Refuse to fill when the prescription is not for a legitimate medical purpose or is outside usual professional practice
- Never “partially comply” with an order you believe is forged or clearly diversionary just to avoid conflict
- Minnesota Alignment: Chapter 152 and the PMP Overlay
Minnesota’s controlled-substance framework lives primarily in Minn. Stat. chapter 152 . For MPJE purposes, treat Minnesota schedules as aligned with the federal CSA architecture : the same five-schedule logic, the same idea that CI is not for ordinary prescribing, and the same principle that CII is the most tightly controlled prescribed class.
Two Minnesota overlays matter even in a “federal foundations” chapter:
1) Minnesota may be stricter
NABP’s MPJE does not split “federal questions” from “state questions” on the score report. If Minnesota imposes a tighter refill, reporting, security, or prescribing rule than the federal floor, answer under prevailing Minnesota law . Federal law is the baseline; Minnesota is the jurisdiction that licenses you.
2) Minnesota PMP reporting is broader than “just opioids”
Under Minn. Stat. §152.126 , dispensers report controlled substances to the Minnesota Prescription Monitoring Program. Exam-critical scope:
Schedules II, III, IV, and V are reportable when dispensed
Minnesota also requires reporting of butalbital-containing products and gabapentin , even though learners often misclassify those agents as “not real CS issues”
That means a technically correct federal schedule answer can still produce a wrong PMP answer if you forget Minnesota’s extra reporting drugs. Later sections drill the operational PMP duties; memorize the reporting scope now so it becomes automatic.
Scheduling Changes and “Who Decides?”
Federally, scheduling authority involves the DEA and scientific/medical evaluation processes (with HHS/FDA input under the CSA framework). States can schedule or control substances under state law as well. If a drug is controlled under Minnesota law even when federal status is evolving, Minnesota practice and board expectations still control your conduct as a Minnesota pharmacist. Exam items may mention rescheduling of a product (for example, historical hydrocodone combination product movement into CII)—use the schedule stated in the vignette and apply current rule logic for that schedule.
Connecting Schedules to Later Federal Rules (Preview)
Keep this cheat-map in your head as you move through the rest of Chapter 2:
- Topic CI CII CIII–CIV CV
- Ordinary Rx dispensing No Yes Yes Yes
- DEA Form 222 / CSOS to order Yes (if handled) Yes No No
- Federal refills N/A None ≤5 within 6 months More flexible federally
Inventory exact-count sensitivity Highest control environment Exact count rules tightest for open CII bottles Estimate rules may apply in some open-bottle situations Same general CS inventory system
Common Exam Traps
Treating adult-use cannabis as federally rescheduled because the state legalized it (only FDA-approved products and marijuana under a state medical marijuana license moved to Schedule III in 2026)
- Assuming Schedule V equals OTC or “no records / no PMP”
- Forgetting corresponding responsibility and thinking only the prescriber can be wrong
Memorizing brand names without knowing whether the product is CII vs CIII (especially combination opioids and buprenorphine products)
- Answering a Minnesota item with the federal minimum when Minnesota reporting or practice rules are stricter
- Study Checklist
Before you leave this section, be able to:
State the three legal criteria that separate the schedules
Place common opioids, stimulants, benzodiazepines, buprenorphine, and pregabalin into the correct schedule band
Define corresponding responsibility in one sentence and apply it to a red-flag vignette
Explain how Minn. Stat. ch. 152 and §152.126 (PMP: II–V + butalbital + gabapentin) interact with federal scheduling
Default to the stricter Minnesota answer when federal and state standards conflict
Master the schedule logic first. Every Form 222, partial-fill, inventory, and theft scenario in the next three sections is just schedule rules applied under operational pressure.